Kornimate/medical-research-clean huggingface dataset:
yoga for symptoms of nerve damage caused by chemotherapy

Conditions: Breast Cancer; Peripheral Neuropathy; Gynecologic Cancer

Summary: some types of chemotherapy used to treat breast cancer can cause damage to nerves with symptoms like tingling, numbness, muscle weakness, and pain in the hands and feet that can last and can affect functioning. the purpose of this study is to find out the effects of yoga on reducing symptoms caused by such nerve damage.


Eligibility criteria:
inclusion criteria: * english-speaking * age \>/= 18 years old * survivors with a primary diagnosis of stage i-iii breast, ovarian uterine, or endometrial cancer * moderate to severe chemotherapy induced peripheral neuropathy, defined by symptoms such as numbness, tingling, or pain ratings of 4 or greater on a 0-10 numeric rating scale * have completed neurotoxic chemotherapy, i.e. taxanes (paclitaxel, docetaxel) and platinum (carboplatin) at least 3 months prior to enrollment * if taking anti-neuropathy medications, they are on a stable regiment (no change in 3 months) * ecog performance status 0-2 exclusion criteria: * participants with metastatic disease * participants who are currently receiving physical therapy or practicing yoga for any reason control group - inclusion/exclusion criteria inclusion criteria: * english speaking * age \>/= 18 years old * survivors with a primary diagnosis of stage i-iii breast, ovarian, uterine, or endometrial cancer * cipn symptoms such as numbness, tingling, or pain ratings \< 2 on a 0-10 nrs scale * have completed neurotoxic chemotherapy, i.e. taxanes (paclitaxel, docetaxel) and platinum (carboplatin) at least 3 months prior to enrollment * ecog performance status 0-2 exclusion criteria: * patients with metastatic disease * patients taking anti-neuropathy medication * patients who are currently receiving physical therapy or practicing yoga for any reason

Keywords: breast cancer neuropathy peripheral neuropathy yoga 17-449
music listening to lower anxiety during ect treatment.

Conditions: Anxiety State

Summary: the purpose of this study is to assess whether music listening is helpful in lowering anxiety in patients about to start their ect treatment.

in-patients at a psychiatric hospital referred to ect treatment, is offered to participate in the study investigating whether listening to expert-curated playlists before-, during and after ect treatment is helpful as a non-pharmacological intervention in lowering patients anxiety. after written informed consent, participants will be randomised into two groups, one listening to playlists with music, one listening to sounds from nature (e.g. rain, ocean waves). playlists will be administered by tablet+earphones in the waiting room, tablet+speaker in the room of procedure and tablet+bedside speaker in the recovery room.

Eligibility criteria:
inclusion criteria: * capable in-patients of age at aalborg university hospital, psychiatry - departments s7 * s8, diagnosed with unipolar or bipolar depression, referred to ect treatment. * patients assessed to fit the study, by the head of departments s7 \& s8 * voluntary participation in the study after written informed consent. * patients can withdraw their consent at any point during the treatment trajectory. exclusion criteria: * patients not compliant with the study, as assessed by head of departments * non-capable patients * patients who withdraw their written informed consent * patients using hearing aid * patients with former ect treatment experience * patients who receive acute ect treatment

Keywords: anxiety state unipolar depression expert-curated playlists ect
genomics of sudden cardiac arrest

Conditions: Death, Sudden, Cardiac

Summary: sudden cardiac arrest (sca) is a sudden, unexpected loss of heart function. it is a leading cause of death, and more than 400,000 people in the united states die each year as a result of sca. this study will analyze genetic samples of people who have experienced sca and people who have not experienced sca to determine if there is a genetic basis for sca.

sca occurs when the heart suddenly and unexpectedly stops beating. when this happens, blood stops flowing to the brain and other vital organs. ninety-five percent of people who experience sca die from it, most within minutes. sca is usually caused by abnormal heart rhythms, known as arrhythmias, which can be triggered by several factors, including coronary artery disease, physical stress, and structural changes in the heart. certain genetic factors may also increase the likelihood of experiencing sca. study researchers will analyze genetic samples from people affected by sca and people unaffected by sca to identify and characterize genetic variations that are associated with an increased risk of sca in european americans and african americans. this study will examine previously collected blood samples from people who have experienced sca and were participants in the cardiac arrest blood study (cabs) and the cardiovascular health study (chs). these participants will not attend any study visits or be contacted by study researchers. people who experience sca in the first 4 years of this study will have blood drawn from paramedics at the time of sca. if these participants survive, they will be asked whether study researchers can review their medical records. study researchers will also examine previously collected blood samples from participants who have not experienced sca and were participants in cabs, chs, and the heart and vascular health study. these participants will not attend any study visits or be contacted by study researchers. study researchers will also enroll a new control group of people who have not experienced sca. these participants will attend one study visit for blood collection and a medical record review.

Eligibility criteria:
inclusion criteria for people with sca: * experienced incident sca inclusion criteria for people without sca: * matched to people with sca on age, gender, and ethnicity exclusion criteria for people with sca and without sca: * members of a vulnerable population

Keywords: sudden cardiac arrest
a pharmacogenomic exploration of lacosamide response

Conditions: Epilepsy

Summary: this is an observational study exploring the genetics of lacosamide response. the study will last 3 years and has been divided in to three stages; 1) recruitment, 2) observational phase, 3) genotyping and analysis. patients initiating lacosamide are recruited and their baseline seizure frequency is assessed retrospectively. patients are then monitored for 18 months with an assessment (via interview and where possible seizure diaries) of seizure frequency and other treatment related phenotypes every 3 months. the recruitment period will span months 1-12, the observational period will span months 1-30 and analysis of data will be conducted between months 30-36 (see figure 2 below). target sample size is 610. primary objective: to determine the clinical relevance of genetic variation in predicting lacosamide responsive and non-responsive patients. secondary objectives: to determine the clinical relevance of genetic variation in predicting: * optimal dose of lacosamide * adverse drug reactions to lacosamide


Eligibility criteria:
inclusion criteria: * diagnosed with partial onset seizures (simple and/or complex) with or without secondary generalization (based on 1981 ilae seizure classification scheme) * over 18 and under 65 years of age at date of recruitment in to the study * currently undergoing pharmacological treatment for refractory partial epilepsy ('refractory' here refers to patients who continue to have seizures despite treatment (current) with two or more appropriate anti-epileptic drugs at appropriate doses) * deemed suitable for treatment with lacosamide (following drug guidelines) exclusion criteria: * patients experiencing seizure type other than partial onset seizures (with/without secondary generalisation) * patients with a history of chronic alcohol or drug abuse within previous 3 years. * non refractory epilepsy patients * patients suffering any other clinically significant disease e.g. cancers, progressive neurological disorder, heart failure, respiratory failure etc * patients who are pregnant or who are intending on getting pregnant within the period of the trial.
phase i study of the safety, tolerance, and pharmacokinetics of 9-[2-(bispivaloyloxymethyl)phosphonylmethoxyethyl]adenine (bis-pom pmea; adefovir dipivoxil) in hiv-infected patients

Conditions: HIV Infections

Summary: to study the safety, tolerance, and pharmacokinetics of a single dose of bis-pom pmea (adefovir dipivoxil) when administered by the oral route in patients with hiv infection.

five patients are entered at each of three dose levels of bis-pom pmea administered orally in a single dose.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * azt, ddi, or ddc (provided patient has been on a stable regimen for at least 4 weeks prior to study entry). * prophylactic aerosolized pentamidine, fluconazole, ketoconazole, trimethoprim/sulfamethoxazole, or dapsone (provided patient has been on a stable regimen for at least 4 weeks prior to study entry). patients must have: * documented hiv infection or diagnosis of aids. * life expectancy of at least 3 months. prior medication: allowed: * prior azt, ddi, or ddc. * prophylactic aerosolized pentamidine, fluconazole, ketoconazole, trimethoprim/sulfamethoxazole, or dapsone. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * active, serious infections (other than hiv infections) that require parenteral antibiotic therapy. * clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia. * gastrointestinal malabsorption syndrome or inability to receive oral medication. concurrent medication: excluded: * diuretics. * amphotericin b. * aminoglycoside antibiotics. * parenteral antibiotics. * other nephrotoxic agents. * other investigational agents. * non-steroidal anti-inflammatory drugs. * aspirin. prior medication: excluded within 2 weeks prior to study entry: * diuretics. * amphotericin b. * aminoglycoside antibiotics. * parenteral antibiotics. * other nephrotoxic agents. * other investigational agents. excluded within 3 days prior to study entry: * non-steroidal anti-inflammatory drugs. * aspirin. active substance abuse (including alcohol or drug abuse).

Keywords: acquired immunodeficiency syndrome aids-related complex antiviral agents adenine
school-based group acceptance and commitment therapy for adolescents

Conditions: Depressive Symptoms; Anxiety; Stress

Summary: the objective of the investigators' mental health promotion intervention premised on the acceptance and commitment therapy (act) framework in secondary school settings aims to enhance young people's psychological flexibility and reduce their emotional distress. act is an evidence-based approach that encourages individuals to act in alignment with their identified values. the investigator's team will employ an act protocol for adolescents developed by louise hayes and joseph ciarrochi. the study includes a single-group study design. the investigator will compare the pre- and post-intervention data to assess the feasibility and potential effectiveness of the group intervention.


Eligibility criteria:
inclusion criteria: eligible participants are adolescents who reported mild to moderate severity of psychological distress, including those who report: * a score of 5-19 on the patient health questionnaire (phq-9), or * a score of 5-14 on the general anxiety disorder-7, or * a score ≥14 on the perceived stress scale. exclusion criteria: adolescents will be excluded if they exhibit or report: * violent or aggressive behavior, or * active self-injurious or suicidal thought, or * active psychotic symptom.
evaluation of aerosol in a dental clinic

Conditions: Covid19

Summary: the purpose of this study is to evaluate the effectiveness of external evacuation units and mouth rinses during aerosol generating procedures in a dental clinic and to determine the risk level to the dental practitioners during aerosol generating procedures.


Eligibility criteria:
inclusion criteria: * prepping natural teeth at the appointment * at least an hour long procedure * procedure will be the first one in the morning
a study to evaluate ssgj-707 in advanced gynecologic cancer patients

Conditions: Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

Summary: this is an open, multicenter phase ii clinical study of ssgj-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. the objective is to evaluate the safety, tolerability and antitumor activity of ssgj-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.


Eligibility criteria:
inclusion criteria: 1. age:18-75 years old 2. advanced endometrial cancer and platinum-resistant ovarian cancer 3. eastern cooperative oncology group (ecog) performance status of 0-1. 4. expected survival \>=12 weeks. 5. signed informed consent form. exclusion criteria: 1. known uncontrolled or symptomatic central nervous system metastatic disease. 2. adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (national cancer institute common terminology criteria \[nci ctcae\] v.5.0). 3. inadequate organ or bone marrow function. 4. pregnant or breast-feeding woman. 5. known allergies, hypersensitivity, or intolerance to ssgj-707 the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
mood and anti-craving effects of varenicline in psychiatric inpatients

Conditions: Smoking; Depressive Disorder

Summary: this study of psychiatric inpatients will assess mood effects of varenicline, as well as assess if varenicline decreased nicotine cravings acutely. this study will also measure side effects of varenicline when given in addition to other psychiatric and non-psychiatric medications.

this study will measure mood effects and rapid anti-craving effects of varenicline in psychiatric inpatients. patients will be offered to participate in the trial if they wish to stop smoking or wish to decrease nicotine cravings while in the hospital. they will not be able to use nicotine replacement products when taking varenicline. patients will be assessed with the qids-sr16, minnesota nicotine withdrawal scale as well as the frequency, intensity, and burden of side effects (fiser) at baseline and daily during the trial; patients will be asked to enroll for the duration of their hospitalization. patients will be assessed as to whether they wish to continue varenicline post-discharge.

Eligibility criteria:
inclusion criteria: 1. admission to butler hospital during study period. 2. current tobacco users ages 18-65. 3. able to give written, informed consent. exclusion criteria: 1. past adverse reaction to varenicline. 2. treatment with varenicline on admission to butler hospital. 3. renal failure or dialysis (3) current pregnancy or breastfeeding.

Keywords: craving smoking depression
a study using botulinum toxin type a as headache prophylaxis for migraine patients with frequent headaches

Conditions: Migraine Disorders

Summary: this is a 60 week study including a double-blind phase followed by an open-label phase.


Eligibility criteria:
inclusion criteria: * frequent migraine (\>=15 headache days per month) * \>=4 distinct headache episodes lasting \>=4 hours * \>=50% of baseline headache days migraine/probable migraine days exclusion criteria: * previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype * any medical condition that puts the patient at increased risk with exposure to botox * diagnosis of complicated migraine, chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache * use of prophylactic headache medication within 28 days prior to week -4 * unremitting headache lasting continuously throughout the 4-week baseline period * known or suspected tmd * diagnosis of fibromyalgia * beck depression inventory score \>24 at week-4 * psychiatric problems that may have interfered with study participation
a study of shr-4375 in subjects with solid tumors

Conditions: Solid Tumors

Summary: this is an open-label, three-part study to evaluate the safety and efficacy of shr-4375 for injection in subjects with solid tumors.


Eligibility criteria:
inclusion criteria: 1. the subjects voluntarily joined the study and signed the icf. 2. measurable disease, as defined by recist v1.1. 3. the eastern cancer cooperative group (ecog) performance status of 0 or 1. 4. life expectancy ≥ 12 weeks. 5. subjects with cytologically or histologically confirmed advanced solid tumors who have failed or are intolerant to standard therapy, have no standard therapy, or refuse standard therapy. exclusion criteria: 1. symptomatic, untreated or active central nervous system metastases. 2. with any active autoimmune disease or history of autoimmune disease. 3. patients with active hepatitis b or hepatitis c. 4. severe infections prior to initiation of study treatment.
assessment of duration of erection with vardenafil 10 mg

Conditions: Erectile Dysfunction

Summary: this study assessed the effect of 10mg vardenafil, taken on demand in an 'at home' setting, as compared to placebo (dummy medication with no pharmacological activity), on the duration of erection from the moment when the patient perceived his erection to be hard enough for penetration until withdrawal from the partner's vagina leading to successful completion which may or may not have included ejaculation. the patient used the stopwatch for the above assessments. the efficacy of oral ed treatments is measured by questionnaires and patient diaries.


Eligibility criteria:
inclusion criteria:- males with erectile dysfunction- stable heterosexual relationship exclusion criteria:- primary hypoactive sexual desire- history of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months nitrate use

Keywords: erectile dysfunction vardenafil
the yield of artificial intelligence (gi genius) in lynch syndrome - a randomized tandem-colonoscopy trial

Conditions: Lynch Syndrome

Summary: we aim to investigate the incremental detection rate of polyps using ai- assisted colonoscopy compared with high-definition white-light endoscopy (hd-wle). we will conduct a single-center randomized tandem colonoscopy trial of patients with lynch syndrome with and without ai. patients will undergo tandem colonoscopy, the second colonoscopy with either hd-wle or an ai- assisted device.

we will include patients with a known pathogenic variant (pv) / likely pv in one of the mmr genes, who are undergoing endoscopic screening and surveillance in our institute. patients will undergo a first colonoscopy with hd-wle, and will be randomized at 1:1 ratio to undergo a second colonoscopy with either hd-wle or an ai- assisted device. all visualized polyps will be removed and size, histology and numbers of polyps detected on each exam will be recorded. we will evaluate the adenoma detection rate and polyp detection rate in each arm and the number of adenomas / polyps in each arm.

Eligibility criteria:
inclusion criteria: * patients with a known pathogenic variant in one of the mismatch repair genes, who are undergoing endoscopic screening and surveillance in our institute exclusion criteria: * patients \< 18 years old * lack of informed consent * concomitant inflammatory bowel disease * previous total colectomy * inadequate bowel cleansing (boston bowel preparation scale (bbps) ≤5 or \< 2 in one of the 3 segments)

Keywords: lynch syndrome artificial intelligence tandem colonoscopy
study to assess safety and efficacy of ifetroban for treatment of portal hypertension in cirrhotic patients

Conditions: Portal Hypertension; Liver Cirrhosis

Summary: this placebo-controlled study will assess the safety and efficacy of a 90-day course of treatment with ifetroban for portal hypertension in cirrhotic patients


Eligibility criteria:
inclusion criteria: * liver cirrhosis * baseline hepatic venous pressure gradient (hvpg) \>= 8 mmhg and \<= 18 mmhg * stable liver function enzymes exclusion criteria: * portal or splenic vein thrombosis * transjugular intrahepatic portosystemic shunt (tips) or portocaval shunt * variceal bleed in last 2 months * hemodialysis * child-pugh score \>= 12 * model for end-stage liver disease- sodium score (meld-na) \>= 20 * acute kidney injury, chronic kidney disease and/or serum creatinine \>= 2.0 mg/dl * current alcohol consumption \> 2 drinks per day * platelet count (plt) \< 60 x 10\^3/microliter (ul) * a change in statin therapy in the last 3 months * current hepatitis virus b or c (hbv or hcv) therapy; or planned initiation of therapy during the treatment period * myocardial infarction within 30 days * history of bleeding diathesis or current (within previous 14 days) or planned use of anticoagulant or antiplatelet drugs including aspirin
teamstepps in school mental health

Conditions: Child Behavior Problem; Multidisciplinary Communication; Interprofessional Relations

Summary: team strategies and tools to enhance performance and patient safety (teamstepps) is an evidence-based approach for teams that can be adapted for school mental health. teamstepps has been widely disseminated in health care settings with promising outcomes. teamstepps is designed to build competencies in the areas of leadership, situation monitoring, mutual support, and communication and has been associated with improvements in teamwork and communication as well as patient outcomes, such as decreased seclusion in psychiatric hospitals. this approach has yet to be extended as an implementation strategy in school or community mental health teams. if an evidence-based team approach like teamstepps can be successfully applied to school mental health teams, it could provide a cost-effective strategy for improving student mental health services and bolstering existing ebp implementation efforts, which to date generally have been insufficient in producing long-term clinician behavior change. in aim 1 the investigators will capture key stakeholder perspectives about challenges in collocated school mental health services through formative work to inform collaborative planning and capacity building activities in aim 2. then, in aim 2 the investigators will identify inter-organizational challenges and required components of teamstepps to adapt. the investigators will establish an advisory board and adapt teamstepps. the product of aim 2 will be an adapted teamstepps, directed toward both school mental health and school-employed personnel, and specific, tailored implementation strategies to improve services in schools in conjunction with teamstepps. finally, in aim 3 the investigators will explore the feasibility, acceptability, and utility of teamstepps and the strategies generated in aim 2 on inter-professional collaboration, teamwork, and student outcomes in eight schools.


Eligibility criteria:
inclusion criteria: * must be one of the following: mental health providers, teachers, leaders from schools (e.g., principals), leaders from community mental health agencies (i.e., executive directors, clinical supervisors), and leadership personnel from the payer or partner school district. exclusion criteria: * there are no exclusion criteria proposed for school and agency-employed personnel. participants will not be excluded given their gender, demographics, and/or past experience.

Keywords: school-based mental health teamstepps